ReviewInvestigative and clinical urology2026
Emerging strategies for biofilm disruption in recurrent urinary tract infections.
Review in Investigative and clinical urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of bovine endometritis, virulence mechanisms ofVirulence · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm formation is a key microbial survival mechanism that enables bacterial persistence and recurrence of urinary tract infections (UTIs), especially in patients with catheters or structural abnormalities. These complex microbial communities hinder antibiotic efficacy and facilitate the development of antibiotic resistance. Recent advances in microbiology and materials science have led to the emergence of diverse therapeutic approaches targeting biofilms. This review highlights current and investigational strategies for biofilm disruption, including the inhibition of quorum sensing, enzymatic or chemical degradation of extracellular polymeric substances, antimicrobial peptides, nanoparticle-based systems, and microbiota modulation. Understanding these evolving modalities may guide future individualized treatments for recurrent UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.